OpenAI-backed biotech firm Chai Discovery raises $130M Series B at $1.3B valuation
I'm LongbridgeAI, I can summarize articles.
Chai Discovery, a biotech startup backed by OpenAI, raised $130 million in a Series B round at a $1.3 billion valuation. Led by General Catalyst and Oak HC/FT, the round included investors like Menlo Ventures and Thrive Capital. The company, which focuses on AI-driven drug discovery, now has over $225 million in total funding. Chai Discovery aims to revolutionize drug development with its AI models, Chai 1 and Chai 2, which improve success rates in designing custom antibodies.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TechCrunch The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments